BRPI0416976A - derivados de 4-fenilpiperidina como inibidores de renina - Google Patents

derivados de 4-fenilpiperidina como inibidores de renina

Info

Publication number
BRPI0416976A
BRPI0416976A BRPI0416976-0A BRPI0416976A BRPI0416976A BR PI0416976 A BRPI0416976 A BR PI0416976A BR PI0416976 A BRPI0416976 A BR PI0416976A BR PI0416976 A BRPI0416976 A BR PI0416976A
Authority
BR
Brazil
Prior art keywords
compounds
formula
coronary syndrome
renin inhibitors
fibrosis
Prior art date
Application number
BRPI0416976-0A
Other languages
English (en)
Inventor
Richard Sedrani
Juergen Klaus Maibaum
Werner Breitenstein
Holger Sellner
Claus Ehrhardt
Nils Ostermann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0416976A publication Critical patent/BRPI0416976A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE 4-FENILPIPERIDINA COMO INIBIDORES DE RENINA". Compostos da presente invenção tendo a fórmula (I) demonstram atividade inibidora sobre a enzima natural renina. Assim, compostos de fórmula (1) podem ser empregados para o tratamento de hipertensão, aterosclerose, síndrome coronária instável, falha cardíaca congestiva, hipertrofia cardíaca, fibrose cardíaca, cardiomiopatia após infarto, síndrome coronária instável, disfunção diastólica, doença de rim crónica, fibrose hepática, complicações resultantes de diabete, como nefropatia, vasculopatia e neuropatia, doenças dos vasos coronários, restenose após angioplastia, pressão intra-ocular aumentada, glaucoma, crescimento vascular anormal, hiperaldosteronismo, prejuízo cognitivo, mal de alzheimer, demência, estados de ansiedade e distúrbios cognitivos.
BRPI0416976-0A 2003-11-26 2004-11-25 derivados de 4-fenilpiperidina como inibidores de renina BRPI0416976A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52537503P 2003-11-26 2003-11-26
PCT/EP2004/013410 WO2005051911A1 (en) 2003-11-26 2004-11-25 4-phenylpiperidine derivatives as renin inhibitors

Publications (1)

Publication Number Publication Date
BRPI0416976A true BRPI0416976A (pt) 2007-02-21

Family

ID=34632979

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416976-0A BRPI0416976A (pt) 2003-11-26 2004-11-25 derivados de 4-fenilpiperidina como inibidores de renina

Country Status (15)

Country Link
US (3) US20070078164A1 (pt)
EP (1) EP1689712B1 (pt)
JP (1) JP4750712B2 (pt)
KR (1) KR20060120146A (pt)
CN (1) CN1906163A (pt)
AT (1) ATE440082T1 (pt)
AU (1) AU2004293177B2 (pt)
BR (1) BRPI0416976A (pt)
CA (1) CA2546264A1 (pt)
DE (1) DE602004022704D1 (pt)
ES (1) ES2332053T3 (pt)
PL (1) PL1689712T3 (pt)
PT (1) PT1689712E (pt)
RU (1) RU2374228C2 (pt)
WO (1) WO2005051911A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0416976A (pt) * 2003-11-26 2007-02-21 Novartis Ag derivados de 4-fenilpiperidina como inibidores de renina
AU2005276624B2 (en) 2004-08-25 2011-09-29 Actelion Pharmaceuticals Ltd. Bicyclononene derivatives as renin inhibitors
EP2248520A3 (en) * 2004-10-08 2010-11-17 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
US7799805B2 (en) 2005-05-27 2010-09-21 Actelion Pharmaceuticals Ltd. Piperidine carboxylic acid amide derivatives
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
NZ569135A (en) 2005-12-30 2011-08-26 Novartis Ag 3,5-Substituted piperidine compounds as renin inhibitors
RU2415840C2 (ru) * 2005-12-30 2011-04-10 Новартис Аг 3,5-замещенные пиперидины, как ингибиторы ренина
GB0611696D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
WO2008074450A2 (en) * 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
EP1987834A3 (en) * 2007-02-13 2008-11-19 Speedel Experimenta AG Substituted piperidines as therapeutic compounds
EP1958634A3 (en) * 2007-02-14 2008-09-24 Speedel Experimenta AG Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease
WO2009000811A1 (en) 2007-06-25 2008-12-31 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US5668151A (en) * 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
PL193686B1 (pl) * 1995-09-07 2007-03-30 Hoffmann La Roche Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
AU3818900A (en) 1999-04-14 2000-11-02 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US20060079533A1 (en) 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
WO2004002549A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
BRPI0416976A (pt) * 2003-11-26 2007-02-21 Novartis Ag derivados de 4-fenilpiperidina como inibidores de renina

Also Published As

Publication number Publication date
EP1689712A1 (en) 2006-08-16
JP4750712B2 (ja) 2011-08-17
CA2546264A1 (en) 2005-06-09
EP1689712B1 (en) 2009-08-19
KR20060120146A (ko) 2006-11-24
RU2006122637A (ru) 2008-01-27
DE602004022704D1 (de) 2009-10-01
AU2004293177A1 (en) 2005-06-09
US20070078164A1 (en) 2007-04-05
PL1689712T3 (pl) 2010-01-29
US7754727B2 (en) 2010-07-13
RU2374228C2 (ru) 2009-11-27
US20080269255A1 (en) 2008-10-30
JP2007512282A (ja) 2007-05-17
ES2332053T3 (es) 2010-01-25
US20100240679A1 (en) 2010-09-23
US8362040B2 (en) 2013-01-29
AU2004293177B2 (en) 2008-10-23
WO2005051911A1 (en) 2005-06-09
ATE440082T1 (de) 2009-09-15
PT1689712E (pt) 2009-11-25
CN1906163A (zh) 2007-01-31

Similar Documents

Publication Publication Date Title
TNSN06156A1 (en) Organic compounds
ATE440082T1 (de) 4-phenylpiperidinderivate als renininhibitoren
WO2004052855A3 (en) Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
JP2013515000A (ja) 血漿カリクレインの阻害薬のプロドラッグ
WO2004052854A3 (en) Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
NO20055246L (no) Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
WO2006094187A3 (en) Phthalazine, aza- and diaza-phthalazine compounds and methods of use
CY1108252T1 (el) Χρηση παραγωγων μεθυλενο αμιδης στις καρδιαγγειακες διαταραχες
TR200103067T2 (tr) Renin inhibitörleri
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
NO20084516L (no) Terfenylderivater for behandling av alzheimers sykdom
WO2004037796A3 (en) 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
CY1117790T1 (el) Ενωσεις αναστολεα 11-βητα-υδροξυστεροειδους αφυδρογονασης τυπου 1
NO20070148L (no) Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
WO2007045551A3 (en) Renin inhibitors nitroderivatives
DE60304047D1 (de) 1-oxa-3-aza-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
WO2003099822A3 (en) 1,2-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
WO2008097953A3 (en) Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
NO20065609L (no) Piperazinderivater av alkyloksindoler.
ATE286898T1 (de) Mercaptoacetylamid-derivate, prozess zur herstellung sowie deren verwendung
WO2008097897A3 (en) Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1(pai-1)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.